Table 3

Recurrences

LGD at GEJ
N=9
Recurrent dysplasia/EAC
N=24
Advanced EAC
N=5
Initial BE
Length, median (P25–P75)C6M7 (4–9; 5–9)C3M5 (1–7; 3–9)C8M10 (5–11; 7–12)
Histology, n (%)
 LGD1 (11)3 (13)
 HGD6 (67)5 (21)2 (40)
 LR-EAC2 (22)16 (67)3 (60)
Severe reflux, n (%)3 (33)1 (4)3 (60)
Treatment
Baseline ER, n (%)5 (56)19 (79)4 (80)
N C-RFA, median (P25–P75)1 (1–2)1 (0–1)1 (1–2)
N F-RFA, median (P25–P75)2 (2–3)2 (1–2)2 (1–3)
FU
Prior IM in cardia, n (%)2 (22)1 (4)0
N FU endoscopies before recurrence, median (P25–P75)3 (1–5)4 (2–5)2 (2–3)
Months between last treatment and recurrence, median (P25–P75)31 (17–45)31 (23–47)25 (18–39)
Months between last FU endsoscopy and recurrence, median (P25–P75)11 (9–13)12 (10–15)12 (7–17)
Recurrence
Location, n (%)
 Cardia9 (100)4 (17)1 (25)*
 Tubular20 (83)3 (75)
DetectionCardia RBxVisible BE a/o lesionVisible BE a/o lesion*
Histology, n (%)
 LGD9 (100)5 (21)
 HGD7 (29)†
 LR-EAC12 (50)†
 HR-EAC5 (100)†
  • *A single patient developed symptomatic, metastasized disease without abnormalities in the oesophagus.

  • †A worst histological grade during FU as compared with baseline, was found in eight patients in total. Three patients with baseline LGD who developed HGD (n=1) or LR-EAC (n=2) and in all five patients who developed HR-EAC during FU.

  • BE, Barrett’s oesophagus; C-RFA, circumferential RFA; EAC, oesophageal adenocarcinoma; ER, endoscopic resection; F-RFA, focal RFA; FU, follow-up; HGD, high-grade dysplasia; IM, intestinal metaplasia; LGD, low-grade dysplasia; RBx, Random biopsies.